Clinical neurology:
In the last seven days, 384 new articles where published in 25 top journals in the field of clinical neurology.
Sort by:
Filters:
Major topics on this page:
The Lancet. Neurology | Letter | 2025 Apr
The Genetic Epidemiology of Parkinson's Disease view.
Farrer MJ and Others
No abstract available
The journal of prevention of Alzheimer's disease | Letter | 2025 Apr
Reevaluating the sleep-dementia link: Methodological gaps and future directions.
Benito-León J and Others
No abstract available
Stroke | Journal Article | 2025 Apr
Practicing Stroke Medicine in War Zones.
Flomin Y and Others
No abstract available
The Lancet. Neurology | Journal Article | 2025 Apr
An operational measurement of brain health: the ABCDS framework.
Avan A and Others
No abstract available
The Lancet. Neurology | Journal Article | 2025 Apr
Gianfranco De Stefano.
No authors listed
No abstract available
The Lancet. Neurology | Letter | 2025 Apr
The Genetic Epidemiology of Parkinson's Disease view - Authors' reply.
Lim SY and Others
No abstract available
The Lancet. Neurology | Journal Article | 2025 Apr
The artist and the scientist join forces for rare diseases.
Morgan J
No abstract available
The Lancet. Neurology | Journal Article | 2025 Apr
Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time?
Schott JM
No abstract available
Pain | Journal Article | 2025 Apr 1
Reply to Key and Brown.
Edwards RR and Others
No abstract available
Pain | Journal Article | 2025 Apr 1
Reply to Andrassy and Mukhdomi.
Rittner HL and Others
No abstract available
Sleep medicine reviews | Review | 2025 Apr
The impact of pharmacotherapy for premenstrual dysphoric disorder on sleep.
Meth EMS and Others
Premenstrual dysphoric disorder (PMDD) affects a subset of women of reproductive age, characterized by severe mood disturbances and physical symptoms during the luteal phase of the menstrual cycle. Symptoms include mood swings, irritability, anxiety, fatigue, physical discomfort, and disruptions to sleep and circadian rhythms, such as altered melatonin secretion. Despite the prevalence of these symptoms, the impact of PMDD treatments on sleep and circadian markers, like melatonin, remains insufficiently understood. This review examines how dysregulated serotonin signaling, disrupted allopregnanolone activity (a neurosteroid derived from progesterone), and aberrant circadian rhythms contribute to PMDD. It also explores the effects of pharmacological treatments, including selective serotonin reuptake inhibitors, on sleep and melatonin regulation, and how these factors influence treatment outcomes. Additionally, the use of hypnotics and sedatives to manage sleep disturbances in PMDD is considered, weighing their potential benefits and risks. A deeper understanding of the interaction between PMDD symptoms, sleep, and circadian rhythms is crucial for developing more effective treatments. Further research is needed to explore the relationship between symptom management, sleep patterns, and circadian function in PMDD, and to determine how these factors can be optimized to improve clinical outcomes and quality of life for women affected by the disorder.
The journal of prevention of Alzheimer's disease | Letter | 2025 Apr
Mitochondrial dysfunction as the missing link between circadian syndrome and dementia.
Lin YH and Others
No abstract available
Epilepsy currents | Journal Article | 2025 Mar 28
Comprehensive Epilepsy Care: The Key to Cutting Costs and Seizing Better Outcomes.
Rolston JD
No abstract available
The Lancet. Neurology | Review | 2025 Apr
Advances in diagnosis, classification, and management of pain in Parkinson's disease.
Tinazzi M and Others
With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than two-thirds of people with Parkinson's disease live with chronic pain, which can manifest in various stages of the disease, substantially affecting daily activities and quality of life. The Parkinson's disease Pain Classification System overcomes the limitations of previous classification systems by distinguishing between pain related to Parkinson's disease and unrelated pain, while also incorporating clinical and pathophysiological (mechanistic) descriptors such as nociceptive, neuropathic, and nociplastic pain. This system provides a framework for accurate diagnosis and mechanism-based therapy. Alongside the appropriate classification of pain, consideration of treatment approaches that include non-invasive (pharmacological and non-pharmacological) and invasive strategies tailored to specific types of pain will refine and inform research trials and clinical practice when it comes to treating pain in Parkinson's disease.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology | Letter | 2025 Apr
MiRNAs and extracellular vesicles in psychiatry: Potential biomarkers, therapeutic advances, and animal models.
Miquel-Rio L and Others
No abstract available
The Lancet. Neurology | Letter | 2025 Apr
Raising awareness of degenerative cervical myelopathy.
Wardropper JJ and Others
No abstract available
The Lancet. Neurology | Journal Article | 2025 Apr
Pharmacological therapy for cerebral cavernous malformations.
Salman RA and Others
No abstract available
The journal of prevention of Alzheimer's disease | Letter | 2025 Apr
Reply to: Mitochondrial dysfunction as the missing link between circadian syndrome and dementia.
Yu L and Others
No abstract available